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Key Messages (Recommendations to improve patient safety): 
• Assessment of kidney function with estimated glomerular filtration rate (eGFR) 
using CKD-EPI and MDRD formulas is key for correct and safe drug prescribing.  
• Dosing adjustments are generally required when eGFR is below 60 ml/min/1.73 m2  
• When choosing drugs for use in CKD patients consider pharmacokinetics and 
pharmacodynamics characteristics for the best efficacy/safety profile   
• Drug interactions in CKD patients are more frequent for the large number of 
prescribed drugs and for the altered pharmacokinetics 
• Avoid or use with extreme caution drugs which have not been proved effective and 
safe in CKD 
 
Abstract 
Drug safety is a very relevant issue when dealing with patients with chronic kidney disease 
who need vascular access procedures and interventions. Drug dosage adjustment are 
needed for patients with acute or chronic kidney disease (CKD). In CKD patients, the 
estimated Glomerular Filtration Rate (eGFR) is used to guide dose adjustments. 
Determining the influence of renal replacement therapies on drug dosage adjustment is also 
very important. Safety issues for the following drugs used for situations related to vascular 
access are reported: Anticoagulants and antiplatelet agents, antibiotics, antimicrobials for 
catheter lock therapy, thrombolytics, local anesthetics, and painkillers. General principles of 











1. BACKGORUND. Introduction to the use of drugs in Chronic Kidney Disease (CKD) 
patients: assessment of kidney function (estimated glomerular filtration rate using 
CKD-EPI and MDRD formulas) 
 
Dialysis access procedures, from central venous catheter insertion to AV fistula and AV 
grafts placement, are performed in patients with different degrees of renal insufficiency, 
including patients with acute kidney injury (AKI) and chronic kidney disease (CKD) in 
different stages. AKI and CKD can change the pharmacokinetics (PK) and the 
pharmacodynamics (PD) of many drugs (1). Moreover, drug removal by intermittent and 
continuous renal replacement therapies (RRTs) determines the need for evaluating drug 
transport across biological (the peritoneum) and artificial membranes. Identifying drugs for 
which individualization of the treatment regimen will be necessary and consequently 
adjusting drug dosage regimens is important to avoid over dosage and toxicity of the drugs 
and/or their metabolites in renally impaired patients. Therefore, prior to treating patients with 
CKD, one must define kidney function (Figure 1). 
 
Which is the most accurate and reliable index to assess kidney function for drug 
dosing, thus improving drug safety?  
Determination of GFR based on the administration of exogenous substances is not practical 
for routine individual drug dose calculations. Therefore, urinary clearance of inulin (the gold 
standard) is rarely performed except for research purposes. Moreover, determination of 
GFR using an endogenous substance (creatinine), based on the urinary clearance of 
creatinine (CLcr) derived from a 24 h urine collection is of limited clinical value because of 
frequent urine collection errors and analytical interferences with the serum or urine 
creatinine assays as the result of concomitant diseases and drug therapies. Therefore, 
estimated GFR (eGFR) obtained in clinical practice from the measurement of endogenous 
substances such as serum creatinine (Scr) and then combined with patient factors is the 
most commonly used measure to define kidney function (2). eGFR can be measured in 
several different ways (Table 1). However, in those clinical situations and for those drugs 
with a narrow therapeutic index for which dosing individualization is required, where any 
creatinine-based estimation equation is not likely to provide a good estimate of GFR, 
measured creatinine clearance or measured GFR using exogenous markers should be 




Which eGFR equation should be used for assessment GFR as the guide to drug 
dosage regimens?  
 
Several considerations regarding methods to estimate eGFR may guide us to choose the 
best option: 
• Estimating equations are more accurate than measured creatinine clearance, given 
the errors in urine collection (3). 
• Variability in serum creatinine (Scr) assays is a major source of bias, leading to 
differences in reported Scr values among laboratories as well as within laboratories 
over time. Use of isotope dilution mass spectroscopy (IDMS), a method to 
standardize creatinine assays, leads to less variation in eGFR and theoretically more 
consistent drug dosing recommendations across institutions and clinical settings. The 
MDRD Study (4) and CKD-EPI (3,5) equations should be preferentially used with 
IDMS standardized creatinine. 
• Keep in mind that in addition to the effect of GFR, Scr may be influenced by 
differences in muscle mass, diet and tubular secretion. Estimating equations capture 
the average differences in the rate of creatinine generation due to age, sex, race, and 
weight, but they do not capture all factors. Therefore, some individuals will have 
substantially different values of Scr than expected and eGFR will be higher or lower 
than the true GFR. 
• Variations of the Scr assays before the availability of standardized approaches 
affected in the past PK/PD drug studies. This may still determine difficulties in 
interpretation of product label drug dosing recommendations. However, it is not 
conceivable repeating all of the PK studies with standardized creatinine: considering 
that the MDRD equation has a similar performance at lower levels of GFR, where 
drug dose adjustment is frequent, it is still reasonable to use drug the dosing 
adjustments suggested in the product labeling. 
• The Cockcroft and Gault (CG) equation (6) has been shown to overestimate GFR 
with the use of standardized creatinine assays. The CG equation is reported in units 
not adjusted for body surface area, which is appropriate for drug dosage adjustment. 




• The Modification of Diet in Renal Disease (MDRD) equation was developed from 
an extensive sample of patients with known CKD, all of whom had a measured GFR 
< 90 ml/min per 1.73 m2 (4). This equation is now widely reported by clinical 
laboratories around the world whenever Scr is measured. Since the MDRD equation 
overestimates measured GFR in subjects with values > 60 ml/min per 1.73 m2, values 
are only reported for GFR < 60 ml/min per 1.73 m2 (3). Use of IDMS-traceable 
creatinine values in the IDMS-MDRD Study equation results in a more accurate 
eGFR. 
• The CKD-Epidemiology Collaboration (CKD-EPI) equation, derived from studies 
including people with and without CKD, is more accurate than the MDRD equation, 
particularly at higher levels of GFR (5,7).  
• Formulas for eGFR are not accurate in individuals with extremes of body size or 
muscle mass, including the frail, elderly, critically ill, and subjects with unusual dietary 
habits. Kidney function is proportional to kidney size, which is proportional to body 
surface area (BSA). BSA of 1.73 m2 is the normal mean value for young adults. The 
eGFR mL/min/1.73 m2 adjusted for BSA is necessary in patients whose body size is 
markedly different than average. If using eGFR in very large or very small patients, 
multiply the eGFR mL/min/1.73 m2 by the BSA in order to obtain adjusted eGFR in 
units of mL/min. 
2. Drug safety: focus on drugs used for clinical events related to vascular access. 
2.1 ANTIMICROBIAL DRUGS. Many antimicrobial agents are eliminated by the kidneys 
and they require dosing adjustments in patients with CKD; however, several commonly used 
drugs do not require adjustments. Antibiotics should be used at the correct dose (see below 
section 4: dosing of drugs) to avoid under-treatment or, more commonly, drug toxicity. 
Infectious complications are relevant causes of morbidity and mortality in hemodialysis 
patients (8,9). Of particular concern, vascular access has emerged as a major risk factor for 
infection and bacteremia (10). Furthermore, the majority of these bacteremias are caused 
by staphylococci, associated with high rates of mortality (8-25%), recurrence (14.5 to 44%), 
and serious metastatic complications (14.5 to 44%) (11,12). When the source of fever is 
suspected to be access (catheter or graft) related, antimicrobial therapy must reliably cover 
gram-positive species (including methicillin-sensitive S. Aureus), since these organisms 
account for about two thirds of HD access-related bacteremias. Enterococci and gram-
negative organisms account for the majority of the remaining bacteremias and antimicrobial 
therapy should target these organisms as well (12). It has become a common practice 
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treating the febrile HD patient empirically with a combination of parenteral vancomycin plus 
gentamycin or vancomycin plus a third generation cephalosporin (12). With the emergence 
of vancomycin-resistant enterococci, the empiric use of vancomycin in the febrile patient on 
HD has been challenged: CDC published guidelines for the prudent use of vancomycin in 
attempt to prevent the spread of vancomycin resistance (13). In accordance with these 
guidelines, empiric treatment with vancomycin is appropriate in patients with β-lactam 
allergy or in instance when serious infections with β-lactam-resistant gram-positive bacteria 
are likely (12). Continuing treatment, however, depends on culture results. 
The appropriate management of catheter-related infections has become a major challenge 
for physicians and the initial empiric antibiotic therapy should take into consideration the 
frequency of the bacterial isolates in such settings. Staphylococcal species are the most 
prevalent (60 to 100%) bacterial isolates in HD patients with CRB (14,15); in some patients, 
both gram-positive and gram-negative organisms have been isolated from the bloodstream, 
indicating mixed bacteraemia (16,17). These data mandate that empiric antibiotic therapy 
should target both gram-positive and gram-negative organisms. 
For infections with documented sensitivity to cefazolin in anuric HD patients, intravenous 
post-dialysis dosing of cefazolin is both safe and effective. Moreover, empiric treatment of 
non-life-threatening infections with cefazolin alone or in combination with gentamicin may 
be appropriate in HD patients pending culture results (18,19). 
Exit-site infections are common and are recognized by redness, exudation and crusting. 
Topical agents applied to catheter exit site, such as povidone iodine, mupirocin, bacitracin 
zinc and polymixin B sulphate ointments have been proven effective (20,21). Oral rifampin 
or nasal mupirocin ointment reduced the incidence of Staphylococcus Aureus bacteremia 
(22). 
Patient safety issues regarding the use of antibiotics are largely debated (23). The WHO 
suggests that prescribing antibiotics without regard for the patient’s underlying condition and 
whether antibiotics will help the patient, or administering multiple drugs without attention to 
the potential for adverse drug reactions, all have the potential for harm and patient injury. 
When considering CKD patients with end stage renal disease, it should be kept in mind that 





2.2 CATHETER LOCK THERAPY. Catheter-related bacteraemia (CRB) is the most 
relevant CVC related complication, which can lead to catheter removal, because bacteria 
colonize the catheter and may be difficult to eradicate.  
Antibiotic-lock therapy (ALT) is used in addition to systemic treatment for CVC related 
infections. Filling both catheter lumens with a mix of antibiotic and anticoagulant at the end 
of dialysis (catheter locking), antibiotic concentrations inside the catheter reach very high 
levels, much higher than the concentration reached during conventional treatment. The 
catheter lock can remain in place for many hours, when the catheter is not in use and it may 
limit biofilm formation. ALT is particularly important in central venous catheter-related 
infection of intraluminal origin, especially in patients with coagulase-negative staphylococci 
infections. 
Published guidelines on the management of the catheter-related infections are in favour of 
the use of ALT for the treatment of catheter-related infections (24). The in vitro stability of 
antibiotic-heparin combinations in CVCs was studied by Vercaigne et al (25). While 
ciprofloxacin produced immediate precipitation with heparin, cefazolin, vancomycin and 
ceftazidime at 10 mg/ml and gentamycin at 5 mg/ml were successfully incubated with 
heparin (5000 U/ml) for 72 hours in the central venous catheter lumen. Although free 
antibiotic in CVC solution was reduced, the final concentration was still sufficient for an 
effective antibiotic-heparin lock (25).  Good evidence is available to support ALT in the 
prevention of catheter-related bacteriemia in patients on hemodialysis (26,27). However, 
others have reported that the use of ALT may be limited by concerns of antibiotic toxicity 
and the appearance of antibiotic-resistant microbial isolates (28,29). 
Sodium citrate locks are effective for prophylaxis against catheter related infections (30), 
although increased rates of catheter thrombosis have been reported (31). 
Catheter-related blood stream infections are reduced by interdialytic locking with 
Taurolidine, a nontoxic antimicrobial agent. Although the use of a formulation of 1.35% 
Taurolidine in 4% citrate, compared to 5000 U/ml heparin, was associated with a greater 
need for thrombolysis to maintain catheter patency (32), the addition of 500 U/ml heparin to 
Taurolidine-citrate solution avoided the need for thrombolysis without increasing 
bacteremia, with catheter patency comparable to heparin 5000 U/ml (33). A Taurolidine-
citrate(4%)-urokinase (25,000 U) lock solution is now available,  
Locking of catheters with ethanol is a promising technique: the agent is bactericidal, has low 
toxicity, is unlikely to produce resistant organisms, is able to disinfect organisms in biofilms 
and is cheap; ethanol is bactericidal by protein denaturation and is active against a wide 
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variety of organism including Gram-positive bacteria, Gram-negative bacteria and fungi. A 
study has been designed comparing ethanol lock (70%) once a week versus standard 
heparin lock (34), but it recruited a limited number of patients and could not demonstrate a 
benefit of ethanol (35). 
In patients with AV access, the probability of dialysis access-related infection is considerably 
less for patients with native arteriovenous fistulae than for those with synthetic grafts (36). 
Postoperative wound infection as well as poor aseptic technique at dialysis may cause 
infection of the fistula; silent infection in old non-functional clotted prosthetic arteriovenous 
grafts has been recognized as a frequent cause of bacteraemia and morbidity among HD 
patients (12). Patient safety, with the aim of avoiding infectious complications, should always 
be considered, even in the absence of a catheter. 
 
2.3 TROMBOLYTICS. Catheter thrombosis is another relevant problem for patients dialysed 
with a CVC, leading to the use of trombolytic therapy. Urokinase is used in Europe and 
recombinant tissue plasminogen activator in the U.S. for prevention and treatment of 
thrombosis. 
Locking of the catheter with urokinase (5000 IU instilled to each lumen for 30 min) may be 
used to open occluded CVCs (37), but in some patients is ineffective and is suggested in 
those patients who have contraindications to systemic urokinase. High dose intra-dialytic 
urokinase (250000 IU infused into the venous chamber over 3 hours) is safe and effective 
in almost all instances of non-positional malfunction of haemodialysis catheters without 
signs of sepsis; contraindications to high dose systemic urokinase are rare in stable 
haemodialysis outpatients (38). However, it is not indicated in patients with recent trauma 
or surgery. 
Recombinant tissue plasminogen activator, alteplase, has recently been shown to be an 
effective alternative for restoring line patency (39). In addition, a recent randomized trial 
demonstrated that the use of alteplase instead of heparin once weekly, as compared with 
the use of heparin three times a week, as a locking solution for central venous catheters 
significantly reduced the incidence of catheter malfunction and bacteremia (40). It is also 
significantly more expensive than heparin and urokinase, but it can reduce the costs of 
unblocking or replacing clotted CVCs (41). 
 
2.4 PAIN MEDICATIONS - ANALGESICS. In CKD patients analgesic drugs are difficult to 
handle and pain is often under-treated, as renal failure modifies the pharmacokinetics and 
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pharmacodynamics of analgesics. In addition, most analgesics and their active metabolites 
are distributed in different tissues and their distribution volume is frequently altered in renal 
failure. Therefore, it is possible to observe side effects even at low doses of analgesics. In 
addition, many patients with CKD follow complex poly-pharmacy therapies for which there 
is a high risk of drug interactions. 
Before starting treatment of pain, it is always necessary to understand its cause. In the 
general population, different drugs are available for the treatment of acute and chronic pain: 
peripherally acting analgesics (paracetamol and non steroidal anti-inflammatory drugs - 
NSAIDs), centrally acting analgesics (opioids), clonidine, adjuvants (anticonvulsants, 
antidepressants, ketamine), peripheral neuronal blocking. NSAIDs are known for their renal 
toxicity and they should be avoided in renal failure. 
 
Somatic pain well responds to NSAIDs and narcotics. Visceral pain, deep and poorly 
localized, caused by irritation of the serous or distension or ischemic tissue (for example 
pain associated with nephrolithiasis or pancreatitis) responds better to narcotics. In some 
cases, however, the narcotics themselves can exacerbate the problem (for example in case 
of duct obstruction). Neuropathic pain is characterized by excruciating burning pain and is 
frequently associated with hypersensitivity. It may be more responsive to anticonvulsants 
and antidepressants then to opioids. 
The knowledge of formulations, pharmacokinetics, potency and duration of analgesics is 
required for optimal analgesic therapy practice. 
For a good treatment plan must first establish visual-analogue scale pain intensity (Figure 
2), which is broadly classified as follows: mild pain (VAS 1-4), moderate pain (VAS 5-6), and 
severe pain (VAS 7-10). 
Barakzoy and Moss validated in patients with renal failure the three-step scale of the World 
Health Organization for the treatment of pain, achieving adequate analgesia in 96% of 
patients. (42). However, this scheme is not applicable to acute pain for the long kinetics of 
tramadol, methadone and fentanyl; for the treatment of acute pain rapid action and easy 
handling therapy is necessary. With this understanding, the general principles for the 
treatment of chronic pain in CKD are summarized in table 2, while in table 3 a treatment 
algorithm is proposed for acute pain (42,43). 
Analgesic drugs can be administered intravenously or orally. It is a doctor's duty preventing 
the onset of severe pain by early administration of an analgesic rather than waiting until the 
10 
 
patient has severe pain. The goal is the absence of pain, but also the limitation of side 
effects. 
 
2.5 ANESTHETICS. CKD patients present the anaesthetist with a number of clinical 
challenges in part related to altered drug handling, with the production and accumulation of 
active metabolites, and to difficulties with vascular access and fluid balance (44). CKD is a 
risk factor for serious postoperative complications, such as acute renal failure and 
cardiovascular complications, which are associated with an increased morbidity and 
mortality (45). 
Dose adjustments are not usually necessary until GFR falls below 50 ml/min. CKD may 
influence both the pharmacokinetics and the pharmacodynamics of a drug (44). 
Local anaesthetics have two plasma protein binding sites: a high affinity and low capacity 
site, and a low affinity high capacity site on albumin; the albumin binding site becomes 
increasingly important as the plasma concentration of the local anaesthetic increases. 
Metabolic acidosis increases the percentage of unbound drug and this effect is more 
pronounced with bupivacaine (46). 
I.V. anaesthetic agents 
 Propofol pharmacokinetics are unaltered by established renal failure; the time interval 
between cessation of a propofol infusion and eye opening is significantly shorter in 
renal failure patients than controls, although blood propofol concentrations are not 
significantly different on waking (47). 
 Thiopental has an increased volume of distribution and reduced plasma protein 
binding in renal failure and the brain is exposed to a higher free drug concentration 
so the rate of administration should be reduced (48). 
Potent inhalation agents 
 Methoxyflurane anaesthesia may determine elevated serum inorganic fluoride levels 
and polyuric renal failure (serum fluoride levels > 50 μmol/dl were associated with an 
increased risk of renal damage) (49). 
 Enflurane: case reports of renal failure after enflurane anaesthesia suggest that it is 
best avoided in patients with renal dysfunction (50). 
 Desflurane and isoflurane are not associated with renal toxicity and appear safe to 




2.6 ANTICOAGULANTS AND PLATLET AGGREGATION INHIBITORS. The prevalence 
of atrial fibrillation (AF) in end-stage renal disease is high, with an increased risk of stroke 
among these patients with AF compared with the AF population without severe renal 
impairment. Many trials have shown the clinical benefit of oral anticoagulation therapy for 
primary and secondary prevention of stroke in patients with AF. However, current stroke risk 
stratification schemes are based on studies that have deliberately excluded patients with 
severe renal impairment. Indeed, there are no large randomized controlled trials assessing 
the real risk/benefit of full intensity anticoagulation in patients with severe renal impairment. 
In addition, rates of major bleeding episodes in anticoagulated hemodialysis patients with 
AF are high (52). 
Using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS) 
studying patients with AF, Wizemann et al (53) found that warfarin use was associated with 
a significantly higher stroke risk, particularly in those over 75 years of age. This study shows 
that atrial fibrillation is common and associated with elevated risk of adverse clinical 
outcomes, and this risk is even higher among elderly patients prescribed warfarin. The 
effectiveness and safety of warfarin in hemodialysis patients require additional investigation 
(53). 
Many physicians prescribe anticoagulants and antiplatelet medications to prevent 
thromboembolic events and access thrombosis in dialysis patients despite limited evidence 
of their efficacy in this population. Chan et al (54) concluded that warfarin, aspirin, or 
clopidogrel prescription is associated with higher mortality among hemodialysis patients 
(54). 
 
Recently, several novel oral anticoagulants (NOACs, rivaroxaban, dabigatran, apixaban) 
have been tested in large trials involving patients with atrial fibrillation (AF) and venous 
thromboembolism (VTE). All of these new anticoagulants are partially eliminated by renal 
clearance. In CKD patients, therefore, the half-lives of these novel anticoagulants may be 
prolonged, resulting in enhanced antithrombotic activity. On the other hand, there might be 
a higher risk of bleeding in CKD patients with these compounds. 
The ROCKET-AF study (55) tested the efficacy and safety of rivaroxaban, a novel factor Xa 
inhibitor, in 14264 patients with non-valvular AF and additional stroke risk factors compared 
with standard warfarin therapy aiming at an international normalized ratio (INR) of 2.0–3.0. 
Rivaroxaban is predominantly metabolized by the liver, but approximately one-third of the 
drug is cleared by the kidneys. The ROCKET-AF trial excluded patients with an eGFR < 30 
12 
 
mL/min, whereas the daily dose of rivaroxaban was reduced from 20 to 15 mg in patients 
with an eGFR of 30–49 mL/min based on available pharmacodynamic data and 
pharmacokinetic modelling (55). 
In the setting of chronic non-valvular atrial fibrillation or venous thromboembolism, a recent 
systematic review of eight randomized controlled trials among patients with CKD who 
received NOACs compared with those who received vitamin K antagonists (VKAs) identified 
no difference in the risk of stroke and systemic thromboembolism, recurrent 
thromboembolism or thromboembolism-related death, or bleeding. CKD was defined as a 
creatinine clearance between 30 and 50 ml/min (56). Collectively, the NOACs have 
demonstrated efficacy and safety similar to those of the VKAs in patients with moderate 
CKD (CrCl 30–50 ml/min); however, trials evaluating the effect of these agents on important 
clinical outcomes in patients with more severe CKD, including patients undergoing dialysis, 
are lacking (56). 
When planning vascular access interventions, one important safety aspect is the 
management of already established anticoagulant and anti-platelet treatments. Oral 
anticoagulation should be substituted with unfractionated heparin, which can be easily 
monitored with aPTT and stopped the day before surgery. Low molecular weight heparins, 
on the other hand, pose an increased risk of bleeding because they accumulate in patients 
with CKD, unless their activity is monitored by the anti-factor Xa assay, which currently is 
not widely available.   
Patients with CKD, including dialysis patients, are often prescribed platelet aggregation 
inhibitors. However, safety with antithrombotic therapy is a major concern in patients with 
renal impairment, because they are at increased risk of bleeding compared with the general 
population for the concurrent uremia-related platelet dysfunction (57). Therefore, 
understanding strategies of antithrombotic management in patients with CKD is of key 
importance. The most commonly used agents are ticlopidine, clopidogrel, and aspirin, which 
sometimes are combined. 
A systematic review identified sixteen studies including 40,676 patients and found an 
increased bleeding risk for hemodialysis patients treated with combination antiplatelet 
therapy, while there are mixed results for studies using a single antiplatelet agent (58). The 
study also suggested that antiplatelet agents appear to be effective in preventing shunt and 
central venous catheter thrombosis, but not for preventing thrombosis of arteriovenous 
grafts. Considering risks and benefits, the usefulness of antiplatelet agents for the 
prevention of access thrombosis in dialysis patients remains poorly defined. Individual risk 
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stratification taking into account the increased risk of bleeding should be considered before 
initiating antiplatelet agents, especially in combination therapy (58).  
Ongoing treatment with antiplatelet agents is generally stopped before planned vascular 
access surgery because they might increase the bleeding and the overall surgical risk in 
CKD patients. A recent retrospective study in renal transplantation, however, highlighted 
that these drugs are associated with a low risk of bleeding during renal transplantation and 
their use does not seem to be a contraindication for renal transplant surgery (59). The same 
might be true for vascular access surgery, especially when considering risks in patients 
needing urgent interventions for vascular access dysfunction. 
Martinez Salazar et al. (60) reported no bleeding complications after 53 tunneled 
hemodialysis catheter procedures performed in dialysis patients on clopidogrel therapy, 
indicating that cardiologic indications to continue clopidogrel after cardiac procedures can 
be followed with low risks of complications during dialysis catheter procedures.  
After vascular access surgery, benefits and risks of anti-thrombotic medications should be 
considered. The aim of such treatment is increasing the access duration, but its suitability 
for needling is also an important outcome to be considered.  
Antiplatelet agents represent a logical strategy to prevent vascular access failure. 
Clopidogrel activity has been studied in patients with renal function impairment (61), 
although no data are reported in the drug prescribing information. Dose adjustment in 
patients with severe renal failure (GFR 5-15 ml/min) and moderate renal impairment (GFR 
30-60 ml/min) does not appear to be required (61). 
Clopidogrel has been evaluated for prevention of AV fistula non-maturation (62) in a 
multicenter randomized clinical trial. Patients received either clopidogrel or placebo for 6 
weeks after surgery. Although the frequency of access thrombosis within 6 weeks was 
significantly lower in patients receiving clopidogrel (12.2% versus 19.5%), AV fistula non-
maturation was similar (and surprisingly very high) in both groups (61.8% versus 59.5%). 
Anti-thrombotics for prevention of stenosis or thrombosis of AV grafts have also been 
evaluated with randomized trials. Neither warfarin nor aspirin plus clopidogrel prevented AV 
graft thrombosis, but unfortunately they increased the risk of bleeding complications (63,64). 
Dipyridamole plus aspirin produced a modest, although significant, prolongation of primary 
unassisted AV graft survival (65).  
Interestingly, long-term fish oil ingestion (four 1-g capsules/day) in patients with new 
hemodialysis grafts decreased by 22% (although statistically non-significant) the proportion 
of grafts with loss of native patency within 12 months (66). In addition, fish oil improved some 
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relevant secondary outcomes such as graft patency (RR 0.58), rates of thrombosis (RR 
0.50), and angioplasty (RR 0.59). Unexpected benefits on cardiovascular events were also 
observed: improved cardiovascular event-free survival (hazard ratio, 0.43) and lower mean 
systolic blood pressure, indicating a favourable risk/benefit ratio for this pharmacological 
approach (66). 
Systemic anticoagulation for the prevention of dialysis catheter thrombosis is a controversial 
issue for its inherent risk-benefit issues: while it may improve catheter survival, it can also 
increase the risk of side effects, such as bleeding and cardiovascular calcifications due to 
inhibition of vitamin K dependent proteins, such as MGP (Matrix Gla protein) (67,68). 
Warfarin at the mini-dose of 1 mg/day was not effective in preventing thrombus formation 
with hemodialysis catheters, although catheter survival improved in patients with an INR 
greater than 1.00 (69). A retrospective study found a significantly reduced thrombosis rate 
of tunneled catheters using anticoagulation at therapeutic levels (70). Similar results were 
reported in patients anticoagulated after treatment with urokinase for thrombosis (71) and in 
patients at high risk for thrombosis with the maintenance of target INR in the range of 1.5 to 
2.0 (72). Twardowski proposed a stepwise anticoagulation strategy in which the warfarin 
dose, started at 1 mg/day, is titrated upwards until thrombotic episodes resolve (73).  
Thus, anticoagulation appears to be effective in preventing catheter thrombosis, but the 
available evidence is based on retrospective and non-controlled studies, where the risks of 
bleeding, vascular calcification and bone side effects were not assessed. This raises a 
relevant safety issue and in the absence of controlled prospective studies confirming the 
overall benefits of anticoagulation use, its general use cannot be currently recommend (74).  
 
3. Interactions of drugs: general principles 
CKD patients are affected by many comorbidities that require multiple pharmacological 
treatments. One of the factors that can modify the response to drugs is the concurrent 
administration of other drugs. This phenomenon is defined as drug interaction. Drug 
interactions may lead to adverse effects and occasionally to fatal outcomes (75). Adverse 
effects due to drug interactions are often predictable from previous reports and careful 
knowledge of pharmacologic principles, but many clinicians have a low awareness of these 
possible adverse events.   
Drug interaction is a condition of pharmacological incompatibilities, in which a drug affects 
the activity of another drug when they are administered together (drug-drug interaction); 
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moreover, this reaction may also happen between drug and food, or between drug and 
medical plants.  
Potential drug-drug interactions have been frequently reported, but only few studies have 
been conducted on actual interactions. Some data are available about drug interactions 
among elderly patients hospitalized for drug toxicity (76). In a recent review (77), differences 
between actual and potential drug-drug interactions (DDIs) were outlined: the incidence of 
actual DDIs resulted lower than that of potential DDIs; important adverse effects occur only 
in the presence of specific risk factors, such as age or genetic polymorphisms.  
There are several mechanisms by which drugs may interact; they can be classified as 
pharmacokinetics, pharmacodynamics, or combined interactions (78,79). Drug action can 
be synergistic (when the drug’s effect is increased), antagonistic (when the drug’s effect is 
decreased), or it may produce new effects. Drug interactions depend both on patient-specific 
factors (intrinsic drug clearance, genetics, gender, concurrent diseases, diet), and drug-
specific factors (dose, route of administration, drug formulation, and the sequence of drug 
administration). 
3.1 Pharmacodynamic interactions Pharmacodynamic interactions can occur 
thought pharmacological receptors or signal transductor mechanisms (79). The drugs may 
or may not act on the same receptor to produce pharmacological effects. When drugs with 
similar pharmacologic effects are concurrently administered, an additive or synergistic 
response is usually seen. 
If the drugs act on the same receptor, they in turn can be:  
- Pure agonists, binding to the receptor’s main locus and causing a similar effect  
- Partial agonists, binding to one of the receptor’s secondary loci, causing the same effect, 
but with a lower intensity in contrast to the principle drug. 
- Antagonists, binding the receptor’s main locus but with an opposite effects to that of the 
main drug. If they compete with the main drug to bind with the receptor, they are defined 
competitive antagonists; instead, when the antagonist irreversibly binds to the receptor and 
it is not released until the receptor is saturated, it is called uncompetitive antagonists. 
3.2 Pharmacokinetics interactions. Different basic pharmacokinetics parameters 
must be considered for obtaining a careful drug management (78).  The most important are 
clearance, distribution volume, amount bound in plasma, half-life.  Clearance is the measure 
of capacity to eliminate the drug, while volume of distribution is the measure of the apparent 
body space available to contain the drug. Moreover, half –life represents the time required 
to reduce the amount of drug in the body by one-half during elimination and attain 50% of 
16 
 
steady state. Finally, the renal eliminated fraction of a drug is the key to predict its 
pharmacokinetics. 
Pharmacokinetics interactions may modify drug concentrations, by interfering with different 
mechanisms such as absorption, distribution, metabolism, and excretion of the drug (78).  
Absorption is strictly related to gastric pH, drug solubility or gastrointestinal motility, while 
distribution is influenced by competition of plasma protein binding, displacement from tissue 
binding sites, or alterations in local tissue barriers.  
Metabolism is regulated by metabolizing enzymes, which are typically activated through 
nuclear receptors. It primary occurs in liver tissue and small intestine, followed by other 
sides, such as plasma, lung and kidney. The most important of this enzymatic system is the 
system of cytochrome P450 isozymes. A result of interactions between endogenous or 
exogenous factors on enzymatic systems may stimulate the function of the enzyme (enzyme 
induction) or inhibit it (enzyme inhibition) (80). The final action is a modification in drug 
metabolism.  
Finally, the excretion interactions principally depend on renal function. Drugs are removed 
from the plasma by the kidney with different mechanisms: passive filtration, reabsorption 
and active secretion. Filtration depends on urine pH, so that renal excretion of certain drugs 
that are weak acids or weak bases may be influenced by other drugs that affect urinary pH 
(for example, drugs acting as weak bases are more easily excreted with acid urine pH, the 
inverse it is true for weak acids). Finally, secretion is a process based on saturability of the 
transported molecule and competition between substrates. P-glycoprotein, organic anion 
and cation transporters are involved in active tubular secretion of some drugs, and inhibition 
of these transporters can reduce renal elimination of the drugs, causing an increase of their 
serum levels (81).  
Considering the key role of the kidneys in drug metabolism and excretion, kidney failure 
obviously modifies drug pharmacokinetics (table 4). 
 
4. Dosing drugs in patients with renal failure 
The standard dose of a drug derives from studies in healthy volunteers and patients with 
normal capacity to metabolize and eliminate drugs (78). However, the effective dose may 
be different from patient to patient. Pathologic conditions (heart, liver or renal failure) may 
demand dosage adjustment in individual patients, because they modify specific 
pharmacokinetic parameters of the drugs. 
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For the predominant role of the kidneys in drug metabolism and excretion, patients affected 
by renal failure require an adjustment of dosing for substances cleared and metabolized by 
the kidney. The principles for drug dosage individualization in CKD patients are summarized 
in table 5. 
Dose adjustment is based on a combination of pharmacokinetics and pharmacodynamics 
effects, determining the relationship between the concentration of a drug and its final effect 
on organs (82). In case of a marked reduction of glomerular filtration, certain drugs should 
no longer be given, either because they may further damage the kidneys or because they 
are insufficiently eliminated and will accumulate, causing adverse events. 
Dosages of drugs cleared by kidney should be adjusted according to creatinine clearance 
or glomerular filtration rate calculated using online or electronic calculators (83), as 
previously outlined. 
A careful assessment of renal function is necessary before starting a drug. It is necessary 
to evaluate if a drug should be administrated or not, and/or if a dosing adjustment is required 
according to glomerular filtration rate.   
Attention in the use of antibiotics is particularly important. Patients with fluid overload may 
require a larger loading dose, in contrast to dehydrated patients. Patients with renal 
insufficiency generally need a higher starting dose, and then the maintenance dose is 
adjusted according to renal function, depending on drug half-life. The starting dose is 
important for both types of antibiotic, those whose effect is concentration-dependent and 
those whose effect is time-dependent. For adjusting the maintenance dosage in patients 
affected by kidney failure, it is possible to reduce the dose or to increase the intervals 
between doses, keeping the dose size normal. In clinical practice, a combination of the two 
methods is often useful. Finally, in patients requiring dialysis many drugs are given at the 
end of the dialysis session, minimizing removal during dialysis.  As a clinical alternative, it is 
often useful to search for drugs that are similar to the principle drugs but not metabolized by 
the kidney (83). 
Detailed dosing recommendations for individual drugs are available in specific textbooks 
(84,85).  Nevertheless, although guidelines are available, indications and regimens must be 
always individualized according to patient response and serum drug concentrations. 
4.1 Problematic drugs in CKD. Many drugs are commonly administered in CKD and 
dialysis patients. Here we focus our attention on drugs required for management of vascular 
access: antimicrobials, anticoagulants, analgesics and anaesthetics. Pharmacokinetic 
parameters may be modified in kidney failure and dosing adjustment based on glomerular 
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filtration rate may be required, especially for antimicrobials (table 6). Again, we want to 
emphasize that patients affected by renal failure are at high risk of adverse events induced 
by  nonsteroidal anti-inflammatory drugs (NSAIDs) (86). The most frequent are acute kidney 
failure, nephritic/nephrotic syndrome, papillary necrosis. In patients with preexisting renal 
damage, the use of NSAIDs can lead to permanent renal damage.  The risk of renal damage 
is increased if NSAIDs are administrated together with ace-inhibitors, in dehydrated 
conditions and for prolonged time. They should be avoided in renal failure. 
4.2 Measurement of therapeutic drug levels. Measuring drug concentrations is one 
way to optimize therapeutic regimens and account for changes between individuals. 
Therapeutic drug monitoring requires availability of rapid, specific, and reliable assays and 
known correlations of drug concentration to therapeutic and adverse outcomes. 
Hypoalbuminemia may influence interpretation of drug concentrations as the total drug 
concentration may be reduced even when the active unbound drug concentration is not. 
Unbound drug concentrations are often not clinically available, and therefore clinicians must 
empirically consider the impact of hypoalbuminemia in their interpretation of measured total 
drug concentrations 
5. CONCLUSIONS 
Safety of pharmacologic therapy in CKD patients is a major concern. Therefore, 
understanding strategies of drug management in this patient population is of key 
importance. The lack of studies performed specifically in patients with impaired renal 
function, particularly those with acute kidney injury or end-stage renal disease, who are 
generally excluded from many large-scale clinical trials, often leads to either no 
recommendation on the most appropriate pharmacologic treatment regimen or to opinion 
based indications. Overall, the choice and combination of drugs prescribed to CKD patients 
should be balanced against the individual risk of adverse events. More data from large-scale 
clinical trials including CKD patients or even better from dedicated studies in patients with 
CKD are warranted, in order to define the most effective and safe drugs for CKD patients. 
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Figure legends  
Figure 1. Clinical algorithm for drug prescribing in CKD patients. 
Figure 2. An example of a visual analogue scale (VAS), where 0 is No pain and 10 is 
agonizing pain. Pain is a subjective sensation and patients can adequately express the 
level of pain they are feeling and the level of pain they consider acceptable using the VAS 
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Table 1- List of the most common formulas for estimating glomerular filtration rate (eGFR), 
used for guiding drug dosage adjustment (see www.mdrd.com) 
Cockcroft and Gault (6)  
MDRD - four-variables (4) Modification of Diet in Renal Disease 





Table 2. General principles for the treatment of chronic pain in CKD patients. 
    
Pain level Recommended analgesic Safety issues 
Mild pain:  
VAS 1–3 
Paracetamol (± adiuvant) is the non-
narcotic agent of choice. 
 
 
NSAID are not indicated (topical 
gels may be used in small amounts) 
Paracetamol: at high doses (over 4 g/day) 
liver toxicity is possible, especially in 
patients with chronic liver disease (viral or 
alcohol related) 
NSAID: increased risk of gastrointestinal 
bleeding; oliguria/anuria due to sodium 
and water retention; hyperkalemia; 
worsening of renal function. 
Moderate pain: 
VAS 4–6 
Tramadol (with dose adjustment 
according to residual renal function)  
Side effects are similar to those observed 
with opioids: 
Constipation; nausea; central nervous 
system depression; seizures (in 
conditions with lower seizure threshold). 
May precipitate excess serotonin activity 
(“Serotonin syndrome”), when patients 
are concomitantly treated with 
serotonergic drugs  
Severe pain: 
VAS 7-10 
Fentanyl (mostly cleared by the 
liver; inactive metabolites) 
 
Buprenorphine (with dose 
adjustment according to residual 
renal function; mostly cleared by the 
liver; inactive metabolites) 
 
Methadone (mostly cleared by the 
liver; inactive metabolites)  
Safe for treatments over short periods; all 
may accumulate in the long term. 
Reassess the need and dose of opioids 
every 24–48 hours. 
Use caution in opioid naïve patients 
(monitor for CNS and respiratory effects). 
Fentanyl and methadone are highly 
protein bound and not dialyzable. 
Constipation; nausea; central nervous 
system depression; seizures (in 
conditions with lower seizure threshold). 
May precipitate excess serotonin activity 
(“Serotonin syndrome”), when patients 










CKD EPI  50-10 ml/min 
male 1.50 < sCr > 5 
female 1.25 < sCr > 4 
CKD EPI  <10 ml/min or dialysis 
male sCr > 5 
female sCr > 4 
mild pain paracetamol 1 g x4; 
tramadol 100 mg may be 
added 
paracetamol 1 g x 3;  
tramadol 50 mg may be added 
moderate pain paracetamol 1 g x4 
+ tramadol 100mg x2; 
buprenorphine 0.15 mg may 
be added 
paracetamol 1 gx 3 
+ tramadol 50 mg x 2 
buprenorphine 0.15 mg may be 
added 
severe pain buprenorphine 0.3 mg x 2 
+ paracetamol 1 g x 4; 
buprenorphine (3rd dose)  
buprenorphine 0.3 mg x 2 
+ paracetamol 1 gr x 3; 







Table 4. Potential effects of kidney failure on drug pharmacokinetics   
 
Absorption  
 Diabetic or uremic gastroparesis may alter gastrointestinal transit time and modify drug 
absorption  
 Drug able to alter gastric pH (e.g. antacids ad phosphate binders) can reduce absorption of 
other drugs  
 Gastrointestinal tract edema caused by congestive heart failure or nephrotic syndrome can 
slow drug absorption 
Distribution 
 Edema or ascites may increase the distribution volume for protein-bound and water-soluble 
drugs  
 Uremia can alter plasma protein binding, affecting acidic drugs  
 Hypoalbuminemia and altered plasma protein binding increase free or unbound 
concentrations of drugs  
 Tissue protein drug binding is reduced in uremic states 
Metabolism 
 Renal failure may affect liver function, increasing or decreasing hepatic biotransformations  
Excretion 
 Reduced excretion and prolonged half-life. Renal failure may alter glomerular filtration, 
tubular secretion, reabsorption 
 




Table 5. Drug dosage individualization in patients with CKD  
 
 eGFR should be calculated for evaluating the stage of CKD and drug dosing purposes  
 Dosing adjustments are generally required when GFR falls below 60 ml/min/1.73 m2 
 The impact of interactions of all drugs commonly used in CKD patients (e.g., phosphate 
binders) should be evaluated 
 The volume of distribution (VD) of many drugs is increased in patients with moderate to 
severe CKD as well as in those with pre-existing CKD who develop AKI. The increase in 
VD may be the result of decreased protein binding or fluid overload. Obese CKD and AKI 
patients and those with large variations in serum protein levels should have their drug 
dosage individualized 
 Dosing changes can involve dose reduction, increasing the interval between doses or both 
 Loading doses may be required if a drug has a long half-life and there is a need to rapidly 
achieve the desired steady-state concentrations or if the VD of a drug is significantly 
increased 
 Patient’s loading dose for increased VD = Usual loading dose x ((Patient’s VD) / (Normal 
VD))  
 Maintenance dose: most commonly, prolonging the dosing interval but maintaining the 
same dose will result in the achievement of similar peak and trough concentrations as well 
as AUC and thus may be preferred.  
 A more accurate drug dosage adjustment is recommended for agents that have a narrow 
therapeutic index. When available, measurement of therapeutic drug levels may optimize 






Table 6. Pharmacokinetic parameters for selected drugs used in CKD/dialysis population and dosing 
































eGFR < 15 
ml/min 
CKD V 
Antiplatelet and Anticoagulant Drugs 
Acetyl-salicylic 








80-90% 0.1-0-2 2 (salycilate)/ 
unchanged 
75-325 mg  
q24 h 





(*) nephrotoxic at high doses (a potential GFR reduction when renal blood flux is supported by prostaglandins); dose 
of 100 mg when administrated as antiplatelet action 





(*) according to INR (international normalized ratio), reduced binding to plasma protein in CKD 








Clopidogrel  50% 98% No data 6-8/No 
data 
75 mg  
q24h 
100% 100% 




100% 100% (*) 
(*) increased risk of bleeding – measure aPTT 
Low molecular 
weight heparin 
- No data 0.06-0.13 22.6/4-10 30-40 mg 
q12h  (*) 
100% 50% (*) 
(*) 1 mg= 100 UI; monitored by anti-Xa factor activity; reduced elimination in renal failure. Avoid in renal failure if 




3% 20-30% 1-2 2/2 500-1000 
mg / q4h  
500-1000 
mg / q 6h 
(*) 
500-1000 
mg / q 8h (*) 
(*) safe in CKD 
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Tramadol 95% 20% 2-3 5-7/11 
(range up 











should not be 
used) 




should not be 
used) 
Buprenorphine 30% (inactive 
metabolites) 







Fentanyl 10%  
 












Codeine >90% 7% 3-4 2.5-3.5/no 
data 
30-60 mg  
q4-6h 
Avoid (*) Avoid (*) 




85-90% 1-8 30/ 2.5-10 mg 
q8-12h 
75% (*) 50% (*) 




Avoid (*) Avoid (*) 
(*) opioid use experienced adverse events in CKD patients 
Antimicrobial Drugs  






















(*) loading dose 500 mg 
Vancomycin 80%    30% 0.4-1.1 4-6/200-
250 
1 g  
q12h 





(*) measure serum levels 














250mg- 2 g 
q6-12 h 
250mg- 2 g  
q 12-24 h 






Ceftazidime  60-80% 5-24% 0.18-0.31 1.2/13-25 1-2 g  
q8h 
1-2 g  
q12-24h 
1-2 g  
q24-48h 
Ceftriaxone 30% 90% 0.12-0.18 7-9/12-24 0.25-2 g 
q12-24h 
100% 100% 






Imipenem  70% 13-21% 0.17-0.3 1/4 0.2mg -1 g 
q6h 
50%  (*) 25%  (*) 




<10% 70%  1.1 1.8/5.0 5-300 mg 
(1-60 ml)  
75% 75% 
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Figure 2: An example of a visual analogue scale (VAS), where 0 is No pain and 10 is 
agonizing pain. Pain is a subjective sensation and patients can adequately express the 
level of pain they are feeling and the level of pain they consider acceptable using the VAS 
 
 
 
 
 
